𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗗𝗮𝘆 𝗔𝗴𝗮𝗶𝗻𝘀𝘁 𝗗𝗿𝘂𝗴 𝗔𝗯𝘂𝘀𝗲 𝗮𝗻𝗱 𝗜𝗹𝗹𝗶𝗰𝗶𝘁 𝗧𝗿𝗮𝗳𝗳𝗶𝗰𝗸𝗶𝗻𝗴 By resolution 42/112 of 7 December 1987, the General Assembly of the United Nations decided to observe 26 June as the International Day against Drug Abuse and Illicit Trafficking as an expression of its determination to strengthen action and cooperation in achieving a world free of drug abuse. 𝗧𝗵𝗲 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗶𝘀 𝗰𝗹𝗲𝗮𝗿: 𝗶𝗻𝘃𝗲𝘀𝘁 𝗶𝗻 𝗽𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗼𝗻 At Aelis Farma, we believe that preventing addiction should include the early detection of drug use disorders to enhance treatment efficacy. Unfortunately, most individuals seek treatment for drug use disorders only when their condition has become severe, making treatment more challenging. Detecting mild drug use disorders and offering treatment at this early stage could be transformative in preventing the progression to addiction. At Aelis Farma, we are dedicated to developing impactful treatment solutions that can make a real difference in people's lives. Currently, we are fully committed to advancing our first drug candidate, AEF0117, for the treatment of cannabis use disorders (CUD). Stay tuned for the results of the phase 2b study of AEF0117 in CUD in Q3 2024. Let's use this day as an opportunity to come together, educate ourselves and others, and support those who may be struggling. Together, we can build healthier, happier communities. #WorldDrugDay #InvestInPrevention #AELIS #cannabis #CUD #addiction #SAMHSA #neurosciences #cognition #CB1
AELIS FARMA’s Post
More Relevant Posts
-
Another example of combination therapy success from KINNOV THERAPEUTICS, a spin-off of Greenpharma S.A.S. ! Check out our new product Oncombo for oncology using drug association. https://lnkd.in/eRtRdR-b #drugcombination #drugassociation #therapy #screening #compoundlibrary #oncology #combinationtherapy
We are thrilled to announce that our spin-off KINNOV THERAPEUTICS obtained ground breaking Phase II results. Please see the article in Addiction Journal (April 10th 2024) entitled: Prazosin and cyproheptadine in combination in the treatment of alcohol use disorder: A randomized, double-blind, placebo-controlled trial. https://lnkd.in/eM-XpUhA The article demonstrates the efficacy of KT-110 in the reduction of total alcohol consumption in patients with severe alcohol use disorder.
To view or add a comment, sign in
-
🔬 From Weight Loss to Addiction Busting: Ozempic's Unexpected Superpowers! 💪 New research published in Addiction journal is turning heads faster than you can say 'semaglutide'! 🤯 Key findings: 40% lower opioid overdose rates 50% reduced alcohol intoxication 500,000+ people studied Who knew those trendy weight-loss shots could be secret weapons against the opioid epidemic? 🦸♀️💉 But hold your horses, folks! As Prof. Fares Qeadan from Loyola University Chicago reminds us, we need more randomized controlled trials before we pop the champagne (responsibly, of course 😉). With 81,000+ opioid-related deaths in the US in 2023, could GLP-1 drugs be the plot twist we've been waiting for? 🎬 Novo Nordisk and Eli Lilly, take a bow – your Ozempic, Wegovy, and Mounjaro might just be the multitasking marvels of modern medicine! 🏆 #HealthcareInnovation #AddictionTreatment #MedicalBreakthrough #ObesityMedicine #PharmaTech #DataDrivenHealth #ClinicalResearch
To view or add a comment, sign in
-
🍃KRATOM is viewed by NIDA National Institute of Drug Abuse as part of the solution to the opioid crisis and not the problem. 🍃Kratom, Director of NIDA National Institute on Drug Abuse has a positive view on kratom. 🍃to the tune of $100 Million dollars, the amount of research spending on kratom. 🍃She believes it’s part of the solution for many. So much so that in her private lab at NIDA she is doing research on KRATOM. 🍃🍃Dec 13 2023 she did a congressional briefing on kratom and told congress to regulate it as other supplements.🍃🍃 NIDA on Kratom addiction safety profile. 2021 NIDA DIRECTOR’S REPORT Nora D. Volkow, M.D. Dir National Institute Drug Abuse. 2 links in this post “initial findings indicate mitragynine and 7-hydroxymitragynine are not rewarding in ICSS procedure. present results suggest kratom alkaloids do not have abuse potential.” https://lnkd.in/gfRDMve3 Here’s the actual scientific paper that NIDA Dir Dr Volkow was referring to @highlight https://lnkd.in/gFp8y79
To view or add a comment, sign in
-
🍃Kratom, Director of NIDA National Institute on Drug Abuse has a positive view on kratom. 🍃to the tune of $100 Million dollars, the amount of research spending on kratom. 🍃She believes it’s part of the solution for many. So much so that in her private lab at NIDA she is doing research on KRATOM. 🍃🍃Dec 13 2023 she did a congressional briefing on kratom and told congress to regulate it as other supplements.🍃🍃 Kratom addictive? NIDA on Kratom addiction safety profile. 2021 NIDA DIRECTOR’S REPORT Nora D. Volkow, M.D. Dir National Institute Drug Abuse. 2 links in this post “initial findings indicate mitragynine and 7-hydroxymitragynine are not rewarding in ICSS procedure. present results suggest kratom alkaloids do not have abuse potential.” https://lnkd.in/gfRDMve3 Here’s the actual scientific paper that NIDA Dir Dr Volkow was referring to https://lnkd.in/gFp8y79
To view or add a comment, sign in
-
🍃Kratom, Director of NIDA National Institute on Drug Abuse has a positive view on kratom. 🍃to the tune of $100 Million dollars, the amount of research spending on kratom. 🍃She believes it’s part of the solution for many. So much so that in her private lab at NIDA she is doing research on KRATOM. 🍃🍃Dec 13 2023 she did a congressional briefing on kratom and told congress to regulate it as other supplements.🍃🍃 Kratom addictive? NIDA on Kratom addiction safety profile. 2021 NIDA DIRECTOR’S REPORT Nora D. Volkow, M.D. Dir National Institute Drug Abuse. 2 links in this post “initial findings indicate mitragynine and 7-hydroxymitragynine are not rewarding in ICSS procedure. present results suggest kratom alkaloids do not have abuse potential.” https://lnkd.in/gfRDMve3 Here’s the actual scientific paper that NIDA Dir Dr Volkow was referring to https://lnkd.in/gFp8y79
To view or add a comment, sign in
-
🍃Kratom, Director of NIDA National Institute on Drug Abuse has a positive view on kratom. 🍃to the tune of $100 Million dollars, the amount of research spending on kratom. 🍃She believes it’s part of the solution for many. So much so that in her private lab at NIDA she is doing research on KRATOM. 🍃🍃Dec 13 2023 she did a congressional briefing on kratom and told congress to regulate it as other supplements.🍃🍃 Kratom addictive? NIDA on Kratom addiction safety profile. 2021 NIDA DIRECTOR’S REPORT Nora D. Volkow, M.D. Dir National Institute Drug Abuse. 2 links in this post “initial findings indicate mitragynine and 7-hydroxymitragynine are not rewarding in ICSS procedure. present results suggest kratom alkaloids do not have abuse potential.” https://lnkd.in/gfRDMve3 Here’s the actual scientific paper that NIDA Dir Dr Volkow was referring to https://lnkd.in/gFp8y79
To view or add a comment, sign in
-
🍃Kratom, Director of NIDA National Institute on Drug Abuse has a positive view on kratom. 🍃to the tune of $100 Million dollars, the amount of research spending on kratom. 🍃She believes it’s part of the solution for many. So much so that in her private lab at NIDA she is doing research on KRATOM. 🍃🍃Dec 13 2023 she did a congressional briefing on kratom and told congress to regulate it as other supplements.🍃🍃 Kratom addictive? NIDA on Kratom addiction safety profile. 2021 NIDA DIRECTOR’S REPORT Nora D. Volkow, M.D. Dir National Institute Drug Abuse. 2 links in this post “initial findings indicate mitragynine and 7-hydroxymitragynine are not rewarding in ICSS procedure. present results suggest kratom alkaloids do not have abuse potential.” https://lnkd.in/gfRDMve3 Here’s the actual scientific paper that NIDA Dir Dr Volkow was referring to https://lnkd.in/gFp8y79
To view or add a comment, sign in
-
Addiction Policy Scholar and Advocate; Humphrey (Fulbright) alumnus; Clinical Social Worker. #ViewsAreMyOwn
Psychedelic substances have significant potential in substance use and mental health disorder treatment. Ibogaine has been a subject of both academic and professional interest for me. During Georgetown University Addiction Policy & Practice Program, I focused on this topic for one of my final projects that was taught by NIDA's deputy director, Wilson Compton. Ibogaine shows promise in treating bipolar disorder, opioid use disorder, and it was even explored as a potential ARV therapy for HIV treatment. However, its use may lead to torsade de pointes, a potentially lethal heart condition. NIDA funded research aimed at eliminating the psychedelic properties and cardiovascular complications of Ibogaine to make it viable for opioid use disorder treatment. It's encouraging to hear about progress, but I think further research is necessary. The illegality of the substance disrupts this process. Countries like Finland, New Zealand, and Uruguay have legalized possession, paving the way for potential advancements in research and practice.
“The National Institute on Drug Abuse, part of the National Institutes of Health, has already begun funding studies (that are not trials involving humans) on ibogaine analogues, chemically related compounds that might provide the therapeutic benefits without the health risks. The agency’s director, Dr. Nora Volkow, said she had long been intrigued by ibogaine’s anti-addiction potential — and wary of its cardiac risks. But existing treatments for opioid use disorder, like methadone and buprenorphine, are imperfect, she noted, and half of all patients stop taking them after six months. “In addition to existing effective medications, there is a need for treatment options that are different from the ones we currently have,” Dr. Volkow said. “We need to break the way we have been doing things and explore what the science is showing us.”
To view or add a comment, sign in
-
🚨 Understanding Xylazine: An Emerging Threat in Canada 🚨 At Spectrum MDX, we strive to keep our clients informed about critical public health trends. Our latest blog post dives deep into the rise of xylazine in Canada and its implications for substance abuse clinics and rehab centers. Learn about: 🔹 Key Findings: Significant rise in xylazine detections since 2019. 🔹 Health Risks: Central nervous system depression, respiratory issues, and cardiovascular effects. 🔹 Treatment Considerations: Monitoring, naloxone administration, and comprehensive care. Stay ahead in providing the best care. Contact us to discover how our custom-made testing cups can enhance your treatment programs. 🔗 Read the full article: https://lnkd.in/encXPiha #PublicHealth #Xylazine #AddictionTreatment #HealthcareInnovation #SpectrumMDX #DrugAwareness #HealthcareProfessionals #PatientCare #OpioidCrisis #DrugSafety #HealthCanada #SubstanceAbusePrevention #AddictionRecovery #PublicSafety #EmergingThreats #ClinicalSupport #HealthcareSolutions #MedicalInnovation #Toxicology #CommunityHealth #DrugEpidemic #HealthEducation #MedicalResearch #HealthcareUpdates #AddictionSupport
Understanding Xylazine: What Substance Abuse Clinics and Addiction Rehab Centers Need to Know - Spectrum Medical
spectrummdx.com
To view or add a comment, sign in
-
We often discuss the medical and therapeutic interventions necessary in substance use management and harm reduction, but emotional components like empathy, love, and understanding also play an important role. When we are working with patients, we make it a point to incorporate this facet of care because feelings of dependency on substances are more than just physiological ailments. “The health outcomes of substance use aren’t linear connections; they are also created and mediated by our socialized views about drugs themselves and the people who use them,” says Beth Meyerson, PhD, director of the Harm Reduction Research Lab in the Arizona University College of Medicine at Tucson. In other words, the stigma that comes with substance use is a complicated barrier to break down. Dating back to the early 1900s, the demonizing of certain narcotic drugs led to the categorization of illicit drugs – opiates, cocaine and marijuana – as a moral issue instead of a health issue. Meyerson’s lab at UArizona is working on a “patient-empowered, trauma-informed methadone treatment protocol” that strives to put the emotions of its participants first and reduce instances of relapse and overdoses. Read more about the UArizona Project Here: #harmreduction #emotionalintelligence #substanceusemanagement #addictiontreatment #addictionscience https://lnkd.in/g25X4gag
Managing substance use disorders with ‘empathy and love’
healthsciences.arizona.edu
To view or add a comment, sign in
3,712 followers